Pancreatic Cancer Research

Clinical trialPhase 2Completed

A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of RC108 for Injection in the Treatment of Patients With c-Met-positiveAdvanced Digestive System Malignant Tumor

Outcome
Finished, no results posted
Phase
Phase 2
Status
Completed
Study type
Interventional
Start
11 November 2022
Ended
31 December 2025
Enrollment
29 participants
Sites
1
Primary outcomes
Objective Response Rate (ORR)
Sponsor type
Industry
Results posted
No
Last update
6 January 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

A multi-center, open-label, study designed to evaluate the preliminary efficacy, safety and pharmacokinetics of RC108 in patients with c-Me-positive advanced digestive system malignancies.

Detailed description public domain (ClinicalTrials.gov)

The primary purpose of this trial is to evaluate the preliminary efficacy, safety and efficacy of RC108 in patients with c-Me positive advanced gastrointestinal malignancies such as gastric, colorectal, esophageal, hepatic, pancreatic and bile duct cancers.